Search by Drug Name or NDC
NDC 61825-0302-60 ORPHENGESIC FORTE 770; 60; 50 mg/1; mg/1; mg/1 Details
ORPHENGESIC FORTE 770; 60; 50 mg/1; mg/1; mg/1
ORPHENGESIC FORTE is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Galt Pharmaceuticals, LLC. The primary component is ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE.
Product Information
| NDC | 61825-0302 |
|---|---|
| Product ID | 61825-302_f187b82e-e331-d676-e053-2995a90a98e7 |
| Associated GPIs | 75990003200320 |
| GCN Sequence Number | 004312 |
| GCN Sequence Number Description | orphenadrine/aspirin/caffeine TABLET 50-770-60 ORAL |
| HIC3 | H6H |
| HIC3 Description | SKELETAL MUSCLE RELAXANTS |
| GCN | 71200 |
| HICL Sequence Number | 001791 |
| HICL Sequence Number Description | ORPHENADRINE CITRATE/ASPIRIN/CAFFEINE |
| Brand/Generic | Generic |
| Proprietary Name | ORPHENGESIC FORTE |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Orphenadrine Citrate, Aspirin and Caffeine |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET |
| Route | ORAL |
| Active Ingredient Strength | 770; 60; 50 |
| Active Ingredient Units | mg/1; mg/1; mg/1 |
| Substance Name | ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE |
| Labeler Name | Galt Pharmaceuticals, LLC |
| Pharmaceutical Class | Anti-Inflammatory Agents, Non-Steroidal [CS], Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE], Centrally-mediated Muscle Relaxation [PE], Cyclooxygenase Inhibitors [MoA], Decreased Platelet Aggregation [PE], Decreased Prost |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA075141 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 61825-0302-60 (61825030260)
| NDC Package Code | 61825-302-60 |
|---|---|
| Billing NDC | 61825030260 |
| Package | 60 TABLET in 1 BOTTLE, PLASTIC (61825-302-60) |
| Marketing Start Date | 2020-06-08 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |